Introduction
============

As survival of patients after heart transplantation (HTX) has been improving in the last decades, malignancy secondary to immunosuppressive therapy has become a major threat to the long-term quality of life and survival.[@b1-dddt-9-093],[@b2-dddt-9-093] Hence, the aim of this study was to investigate the distribution of malignancies in patients after HTX. Special emphasis was placed on the evaluation of risk factors, including immunosuppressive drug therapy, with regard to the occurrence of malignancies and survival after HTX.

Methods
=======

Patients
--------

All human studies were reviewed and approved by the ethics committee of the University of Heidelberg, Heidelberg, Germany, and were therefore performed in accordance with the ethical standards laid down in the 2008 Declaration of Helsinki. A total of 381 patients (age ≥18 years) receiving HTX were included in this retrospective study. All patients were followed-up at the University of Heidelberg Heart Center, Heidelberg, Germany. Data were retrieved from the Heidelberg Registry for Heart Transplantation being collected between 1989 and 2014. Taking the slow-growing nature of cancer into account, adequate length of follow-up after HTX is required. Hence, only patients who survived for a minimum of 2 years after HTX were included.

The mean recipient age at HTX was 51.2±10.5 years, and the mean follow-up period after HTX was 9.7±5.9 years. Three hundred patients were men (78.7% of total). The mean donor age was 38.9±13.5 years. One hundred and sixty-five donors were men (46.9%). The number of treated rejection episodes (TREs) in the first year after HTX was 1.0±1.6. Further patient characteristics are given in [Table 1](#t1-dddt-9-093){ref-type="table"}.

Principal diagnosis for HTX was cardiomyopathy in 217 patients (57.0% of total), coronary artery disease in 128 patients (33.6% of total), amyloidosis in 21 patients (5.5% of total), and valvular disease in 15 patients (3.9% of total).

Follow-up
---------

All patients were routinely followed up at the University of Heidelberg Heart Center, Heidelberg, Germany. After initial hospital stay, patients were seen on a monthly basis during the first 6 months after HTX, then bimonthly until the end of the first year, and thereafter 3 times per year.

Noncutaneous malignancies were considered all forms of cancer not related to skin cancer. The following entities were included in the category of cutaneous malignancies: precancerous lesion, basal-cell carcinoma, squamous-cell carcinoma, and melanoma.

Tumor screening, including conventional chest radiograph in two planes, abdominal ultrasound, dermatological examination, urological/gynecological examination (including prostate-specific antigen or mammography in women \[\>45 years\]), guaiac-based fecal occult blood testing, and cytomegalovirus (CMV) and Epstein--Barr virus (EBV) (viral load determination via polymerase chain reaction), was performed yearly. Endomyocardial biopsies were taken weekly during the first month after HTX, then biweekly for the next 3 months, then at 6-month and 1-year follow-up after HTX, and thereafter once a year (or if clinically indicated). Cardiac catheterization was performed 3 months after HTX, and subsequently, 1 year, 2 years, 5 years, and 10 years after transplantation or if clinically indicated.[@b3-dddt-9-093] TRE were diagnosed according to the revised International Society for Heart and Lung Transplantation (ISHLT) classification.[@b4-dddt-9-093]

Immunosuppressive regimen
-------------------------

Patients after HTX had been receiving anti-thymocyte globulin intravenously (Genzyme GmbH, Neu-Isenburg, Germany), which was guided by the daily performed cluster of differentiation 4+ T-cell monitoring via fluorescence-activated cell sorting (FACS) to adjust the application rate, since 1994.[@b5-dddt-9-093]

The initial immunosuppressive regimen consisting of cyclosporine A (CsA) and azathioprine (AZA) was replaced by CsA and mycophenolate mofetil (MMF) in 2001, and by tacrolimus (TAC) and MMF in 2006. Additionally, mammalian target of rapamycin (mTOR) inhibitors (everolimus/sirolimus) were used from 2003.

The oral dose of CsA was titrated to reach the target trough levels of 50--225 ng/mL depending on time after HTX: \<1.0 year after HTX, 90--225 ng/mL; \>1.0 year after HTX, 70--110 ng/mL; and \>2.0 years after HTX, 50--90 ng/mL. In combination with AZA, each CsA target trough level was increased by 25 ng/mL. AZA was titrated according to white blood cell count, usually by administering 25--150 mg/day. The MMF target trough level was 1.5--4.0 mg/L (alternatively mini-area under the curve 30--60 mg h L^−1^). TAC target trough levels ranged from 3 to 14 ng/mL depending on time after HTX: \<1.0 year after HTX, 6--14 ng/mL; \>1.0 year after HTX, 4--8 ng/mL; and \>2.0 years after HTX, 3--6.5 ng/mL. In patients with significant renal insufficiency, calcineurin inhibitors (CNI) target trough levels were reduced by 30.0%--50.0%. Oral mTOR inhibitor therapy was titrated to achieve target trough levels of 3--8 ng/mL. Levels for sirolimus and everolimus were 4--8 ng/mL in patients \<2.0 years after HTX and 3--6.5 ng/mL in patients \>2.0 years after HTX. Steroids (prednisolone) were weaned off whenever possible 6 months after HTX.

Statistical analysis
--------------------

Statistical analysis was performed with SAS (Version 9.1; SAS Institute, Cary, NC, USA). Student's *t*-test was used for continuous variables and chi-squared test for categorical variables. A *P*-value of \<0.05 was considered to be statistically significant. The Kaplan--Meier estimator using log-rank tests was applied for survival of patients and for recurrence of cutaneous neoplasia after HTX.

Univariate analyses were performed to evaluate the risk of the following variables: recipient age and sex, body mass index (BMI), coronary artery disease, arterial hypertension, dyslipidemia, diabetes mellitus, renal insufficiency, recipient CMV-positive serostatus, recipient EBV-positive serostatus, donor age, donor sex, and number of TREs in the first year after HTX. Further, the influence of the following immunosuppressive drugs was analyzed: CsA, TAC, AZA, MMF, steroids, and mTOR inhibitors.

Additionally, a multivariate analysis with a logistic regression model was performed to estimate the influence of the following four variables: recipient age, recipient sex, diabetes mellitus, and \>1 TRE in the first year after HTX.

Results
=======

Distribution of malignancies
----------------------------

### All malignancies

Of the 381 included patients, there were 251 patients without posttransplant malignancy (65.9% of total) and 130 patients with posttransplant malignancy (34.1% of total). The patients developing a neoplasm were further subdivided into 58 patients with cutaneous malignancy only (15.2% of total), 56 patients with noncutaneous malignancy only (14.7% of total), and 16 patients with both malignancies (4.2% of total) ([Figure 1A](#f1-dddt-9-093){ref-type="fig"}). The mean interval from transplantation until initial diagnosis of malignancy was 7.3±4.7 years, and from diagnosis of malignancy until last follow-up was 4.8±4.3 years.

### Cutaneous malignancies

A total of 74 cutaneous malignancies were documented. Among these malignancies, there were 14 precancerous lesions (18.9% of subgroup), 30 basal-cell carcinomas (40.6% of subgroup), 28 squamous-cell carcinomas (37.8% of subgroup), and two melanomas (2.7% of subgroup) ([Figure 1B](#f1-dddt-9-093){ref-type="fig"}). The mean interval from transplantation until initial diagnosis of a cutaneous malignancy was 7.0±4.1 years, and from diagnosis of cutaneous malignancy until last follow-up was 6.3±4.4 years.

### Noncutaneous malignancies

Seventy-two noncutaneous malignancies were documented, including 58 carcinomas (80.5% of subgroup), eleven posttransplant lymphoproliferative diseases (PTLD, 15.3% of subgroup), and three other hematopoietic neoplasias (myeloma/leukemia, 4.2% of subgroup) ([Figure 1C](#f1-dddt-9-093){ref-type="fig"}). The mean interval from transplantation until initial diagnosis of a noncutaneous malignancy was 7.7±5.3 years, and from diagnosis of malignancy until last follow-up was 3.2±3.5 years.

Risk factors
------------

### Mortality

A total of 114 out of 381 HTX recipients (29.9% of total) died during follow-up. Mortality rate in patients without development of a malignancy was significantly lower than in patients with a malignancy (no malignancy: 59 of 251 patients \[23.5% of subgroup\], malignancy: 55 of 130 patients \[42.3% of subgroup\]; *P*=0.0001).

Patients with only a cutaneous malignancy had a lower mortality rate than patients with only a noncutaneous malignancy (cutaneous malignancy: 18 of 58 patients \[31.0% of subgroup\], noncutaneous malignancy: 31 of 56 patients \[55.4% of subgroup\]; *P*=0.0087). Superior prognosis of patients with cutaneous malignancies only vs patients with noncutaneous malignancies only was confirmed by a Kaplan--Meier analysis (*P*=0.0007).

Sixteen patients had both cutaneous and noncutaneous malignancies (mortality rate was six of 16 patients, 37.5%).

Patients with malignancies vs patients without malignancies
-----------------------------------------------------------

On comparing patients with and without malignancies, statistically significant risk factors associated with an increased risk for malignancy after HTX were as follows: older recipient age (54.3±8.3 years vs 49.6±11.2 years; *P*\<0.0001), male recipient sex (115 of 130 \[88.5%\] vs 185 of 251 \[73.7%\]; *P*=0.0008), and \>1 TRE in the first year (41 of 119 \[34.5%\] vs 51 of 236 \[21.6%\]; *P*=0.0091). Further, metabolic factors such as dyslipidemia (97 of 130 \[74.6%\] vs 159 of 251 \[63.3%\]; *P*=0.0263), diabetes mellitus (59 of 130 \[45.4%\] vs 68 of 251 \[27.1%\]; *P*=0.0003), and renal insufficiency (86 of 130 \[66.2%\] vs 136 of 251 \[54.2%\]; *P*=0.0247), showed a higher risk for the development of a malignancy.

Regarding other comorbidities, including coronary artery disease prior to HTX or arterial hypertension, no statistically significant association with development of a malignancy was found. Additionally, there was no clear evidence in this study for a correlation between the development of a malignancy and positive recipient CMV or EBV serostatus (all *P*≥0.05; [Table 1](#t1-dddt-9-093){ref-type="table"}).

Cutaneous vs noncutaneous malignancies
--------------------------------------

Further subgroup analysis between cutaneous vs noncutaneous malignancies showed no statistically significant difference regarding recipient age or recipient sex (*P*=0.9857 and 0.3179, respectively). Neither did dyslipidemia (*P*=0.9235), diabetes mellitus (*P*=0.2654), or renal insufficiency (*P*=0.1259) differ statistically significantly.

Regarding positive recipient EBV serostatus, there were more patients with cutaneous than noncutaneous malignancies (44 of 58 \[75.9% of subgroup\] vs 32 of 56 \[57.1% of subgroup\]; *P*=0.0340).

Positive CMV recipient serostatus showed no significant difference between subgroups (*P*=0.2654).

Immunosuppressive drug therapy
------------------------------

### Calcineurin inhibitors

Two different CNI agents (CsA and TAC) were compared separately, revealing a significant difference. Patients with CsA for \>1 year (92 of 130 \[70.8% of subgroup\] vs 147 of 251 \[58.6% of subgroup\]) displayed a higher risk for cancer (*P*=0.0195) ([Table 2](#t2-dddt-9-093){ref-type="table"}). In patients with TAC application for \>1 year, a lower risk for the development of a malignancy was found (*P*=0.0002). In these patients, 34 of 130 (26.2% of subgroup) vs 115 of 251 (45.8% of subgroup) developed a malignancy.

### Azathioprine

Administration of AZA for \>1 year was associated with a significantly increased risk for the development of a malignancy (*P*=0.0008). In patients with malignancy, 67 of 130 patients (51.5% of subgroup) were on AZA for \>1 year, compared to only 85 of 251 patients in tumor-free patients (33.9%).

### Mycophenolate mofetil

In contrast to AZA, the use of MMF for \>1 year was associated with a reduced risk for the development of a malignancy (*P*\<0.0001).

### Steroids

Application of steroids for \>1 year showed a higher risk for the development of a malignancy (*P*=0.0018).

### mTOR inhibitors

Administration of mTOR inhibitor therapy for \>1 year after HTX was associated with a statistically significant lower risk for the development of malignancies (19 of 130 patients \[14.6% of subgroup\] vs 85 of 251 patients \[33.9% of subgroup\]; *P*\<0.0001).

Cutaneous malignancy recurrence after 2 years of follow-up (two of 22 \[9.1% of subgroup\] vs 13 of 41 \[31.7% of subgroup\]; *P*=0.0445) as well as after 5 years of follow-up (six of 19 \[31.6% of subgroup\] vs 22 of 31 \[71.0% of subgroup\]; *P*=0.0065) was significantly lower in patients with mTOR inhibitor therapy after the initial diagnosis of a tumor.

A lower mortality with noncutaneous malignancies was observed in patients receiving mTOR inhibitor therapy after the initial diagnosis of malignancy (six of 29 \[20.7% of subgroup\] vs 31 of 43 \[72.1% of subgroup\]; *P*\<0.0001) ([Table 3](#t3-dddt-9-093){ref-type="table"}).

The results regarding the lower cutaneous malignancy recurrence (*P*=0.0202) and lower noncutaneous malignancy mortality (*P*\<0.0001) in patients with mTOR inhibitor therapy after the initial diagnosis of malignancy were confirmed by Kaplan--Meier analysis ([Figures 2](#f2-dddt-9-093){ref-type="fig"} and [3](#f3-dddt-9-093){ref-type="fig"}).

Multivariate risk factor analysis
---------------------------------

Multivariate analysis identified four independent risk factors for increased risk of malignancy: recipient age (odds ratio \[OR\] =2.158; *P*=0.0065); recipient sex (OR =2.967; *P*=0.0019); diabetes mellitus (OR =1.983; *P*=0.0056); and \>1 TRE in the first year (OR =2.199; *P*=0.0032) ([Table 4](#t4-dddt-9-093){ref-type="table"}).

Discussion
==========

Immunosuppressive regimens and treatment options have improved significantly, thereby resulting in better long-term survival rates. In patients with immunosuppressive therapy, occurrence of malignancies after HTX is a well-described phenomenon.[@b6-dddt-9-093],[@b7-dddt-9-093] Hence, this work aims at a better management of HTX patients to minimize tumor-associated mortality and recurrence of malignancies in order to further improve long-term survival after HTX.

The incidence of malignancy after HTX has been reported as being between 21.0% and 31.0% depending on duration and completeness of follow-up.[@b3-dddt-9-093],[@b8-dddt-9-093] In this long-term follow-up study, 130 patients (34.1%) developed posttransplant malignancy. These patients were further subdivided into 58 patients with cutaneous malignancy only, 56 patients with noncutaneous malignancy only, and 16 patients developing both types of malignancies. These numbers are in line with those of Crespo-Leiro et al who observed 50.7% cutaneous malignancies after transplantation.[@b9-dddt-9-093]

In comparison to cutaneous malignancies, mean interval from transplantation until initial diagnosis of tumor was longer in patients with noncutaneous malignancies. On the contrary, the mean interval from diagnosis of malignancy until last follow-up was longer in patients with cutaneous malignancies. Regarding mortality, patients without malignancy had the lowest mortality rate (23.5%), followed by skin cancer (31.0%), patients with both types of malignancies (37.5%), and noncutaneous malignancies (55.4%). These results are in accordance with the poor prognosis of solid tumors after transplantation in immunosuppressed patients.[@b10-dddt-9-093],[@b11-dddt-9-093] Hence, prognosis for post-HTX skin cancer is considerably more favorable than for other post-HTX neoplasias.[@b9-dddt-9-093]

These findings are comparable to those from nontransplanted patients, where skin cancer in general is associated with a lower mortality than noncutaneous cancer.

Demographic data of this study was comparable to those from the International Society for Heart and Lung Transplantation Registry and the Spanish Post-Heart-Transplant Tumor Registry regarding recipient age, percentage of male recipients, and occurrence of malignancies.[@b9-dddt-9-093],[@b12-dddt-9-093]

In this study, older recipient age (*P*\<0.0001), male recipient sex (*P*=0.0008), and \>1 TRE in the first year (*P*=0.0091) were associated with an increased risk of malignancy after HTX.[@b9-dddt-9-093] Also, metabolic factors such as dyslipidemia (*P*=0.0263), diabetes mellitus (*P*=0.0003), and renal insufficiency (*P*=0.0247) seemed to play an important role in the development of malignancies. This is in line with data from the Aerobic Center Longitudinal Study, which revealed a 56% greater age-adjusted risk for cancer mortality in patients with metabolic syndrome.[@b13-dddt-9-093] However, we could not find a statistically significant correlation between the occurrence of a malignancy and coronary artery disease or arterial hypertension (all not significant, *P*≥0.05).

In accordance with above-mentioned findings, subsequent multivariate analysis identified four independent risk factors associated with an increased risk of malignancy: recipient age (OR =2.158; *P*=0.0065); male recipient sex (OR =2.967; *P*=0.0019); diabetes mellitus (OR =1.983; *P*=0.0056); and \>1 TRE in the first year (OR =2.199; *P*=0.0032). Whereas age and sex are inevitable risk factors, diabetes mellitus and rejection episodes offer a therapeutic approach.

In fact, HTX itself was described as a risk factor, as the incidence of malignancies in patients after HTX is two- to threefold higher compared to patients after renal transplantation.[@b14-dddt-9-093] This might be attributed to the fact that patients after HTX require higher doses of immunosuppressive therapy than patients after kidney transplant, resulting in a higher risk of malignancy.

EBV has been reported to be associated with lymphoproliferative disorders, and coinfections with CMV in recipients of solid-organ transplants have been described.[@b15-dddt-9-093],[@b16-dddt-9-093] Nevertheless, no difference between tumor and nontumor patients concerning positive recipient CMV or EBV serostatus was seen in this study (*P*≥0.05).

Also, the effects of different immunosuppressive agents were evaluated in this study. Administration of CsA (*P*=0.0195), AZA (*P*=0.0008), or steroids (*P*=0.0018) for \>1 year after HTX was significantly associated with an increased risk for the development of a neoplastic lesion. This is in line with findings of Wilkinson et al reporting an increased frequency of posttransplant malignancies in patients treated with CsA, AZA, and steroids.[@b17-dddt-9-093] CsA enhances tumor growth and increases the number of metastases by a direct cellular effect that is independent of its effect on the host's immune cells, resulting in an increased production of growth factors.[@b18-dddt-9-093] Increased occurrence of tumors in patients with AZA might be a consequence of the photosensitizing effects of AZA and its metabolites.[@b19-dddt-9-093]

In contrast to CsA, TAC, which is another CNI, showed a significantly lower risk for the development of a malignancy when applied for \>1 year (*P*=0.0002). This might be explained by a shorter follow-up interval in patients on TAC (7.0±4.6 years) compared to CsA (11.8±5.8 years). Nevertheless, the use of TAC instead of CsA as primary immunosuppressant for heart transplant recipients led to a significant reduction in rejection episodes.[@b20-dddt-9-093] Further, a combination of TAC and MMF was more efficacious in preventing rejection episodes than a combination of CsA and MMF.[@b21-dddt-9-093],[@b22-dddt-9-093] However, it may also be speculated that this reduction of rejection episodes may cause less malignancies, because in this study more than one TRE in the first year was associated with an increased risk for tumorigenesis (OR =2.199; *P*=0.0032).

Regarding the use of MMF for \>1 year, there was a reduced risk for the development of a malignancy (*P*\<0.0001). Crespo-Leiro et al showed a lower incidence of skin cancer with MMF than with AZA.[@b9-dddt-9-093] These results were supported by O'Neill et al showing that the use of MMF in standard immunosuppressive regimens is associated with a significantly lower risk of developing malignancy.[@b23-dddt-9-093]

mTOR inhibitors have been shown to prevent tumors and even to reduce metastatic tumor growth by antiangiogenesis.[@b24-dddt-9-093] In this study, the application of mTOR inhibitor therapy for \>1 year after HTX was associated with a statistically significant lower risk for the development of malignancies (*P*\<0.0001), which is in line with data from a multivariate analysis of posttransplant malignancies in patients receiving mTOR inhibitors for maintenance of immunosuppression, showing a significantly reduced risk of developing a posttransplant de novo malignancy in the 2-year follow-up.[@b25-dddt-9-093]

Further, our data show a significant lower cutaneous malignancy recurrence after 2 years of follow-up (*P*=0.0445) as well as after 5 years of follow-up (*P*=0.0065) in patients with mTOR inhibitor therapy after diagnosis of the initial malignancy. Stallone et al reported a complete remission of cancer in transplant patients with cutaneous malignancy after a switch from an immunosuppressive regimen based on CsA and MMF to a regimen based on mTOR inhibitors.[@b26-dddt-9-093] Nevertheless, 1-year follow-up (*P*=0.1928) and overall follow-up (*P*=0.5520) were not significantly different statistically. This could be due to the fact that, on the one hand, the mean interval until recurrence of skin cancer is longer than 12 months, and, on the other, there is only a small number of remaining patients left within the final follow-up, making it more difficult to analyze short-term and very long-term effects.[@b3-dddt-9-093]

Most importantly, we observed lower mortality in patients with noncutaneous malignancies receiving a therapy containing an mTOR inhibitor after the initial diagnosis of malignancy (*P*\<0.0001). These results were confirmed by Kaplan--Meier analysis (*P*\<0.0001). This is supported by experimental work indicating the concept of mTOR inhibitors being able to simultaneously reduce the risk of cancer while avoiding allograft rejection.[@b27-dddt-9-093],[@b28-dddt-9-093] Nevertheless, the use of mTOR inhibitors is not benign, and such therapy is associated with significant side effects that need to be managed appropriately. Many of the side effects can be attenuated by decreasing the dose significantly and maintaining an overlap period with CNI during conversion for a longer period.[@b29-dddt-9-093]

These results regarding mTOR inhibitors strengthen the possibility of an equilibrium between efficient immunosuppressive drug therapy and control over the development of cancer, thereby offering new therapeutic strategies for the treatment of malignancies in clinical practice.[@b30-dddt-9-093],[@b31-dddt-9-093]

Study limitations
-----------------

These findings were derived from a single-center study. However, a study size with 381 patients was sufficient to compare results with multicenter studies and, in contrast to multicenter studies, all patients received an identical induction regimen.

Further, although the data were gathered prospectively, the retrospective nature of this analysis carries the limitations of all such study design.

Conclusion
==========

As a result of the improvements in immunosuppressive regimen and follow-up treatment, long-term survival rates in patients after HTX have significantly increased. However, long-term prognosis is strongly affected by the occurrence of malignancy. This study highlights the complexity of risk factors and immunosuppressive drug therapy on the development of malignancies after HTX. Relevant risk factors for the development of malignancies were older recipient age, male recipient sex, and \>1 TRE in the first year after HTX. Furthermore, diabetes mellitus was an independent metabolic risk factor associated with a higher risk for the development of neoplasms. This underlines the complexity of risk factors that are not only limited to immunosuppressive therapy.

However, most importantly, a therapy containing an mTOR inhibitor after the initial diagnosis of tumor was associated with lower cutaneous malignancy recurrence rates after 2 years and 5 years and lower noncutaneous malignancy mortality, and should therefore be considered as an essential part of a modern immunosuppressive therapy in patients after HTX.
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![Types of malignancies after HTX.\
**Notes:** (**A**) Malignancies after HTX. Two hundred and fifty one patients with no malignancy, 58 patients with cutaneous malignancy only, 56 patients with noncutaneous malignancy only, and 16 patients with both malignancies. (**B**) Types of cutaneous malignancies. Precancerous lesions, 14 patients; basal-cell carcinoma, 30 patients; squamous-cell carcinomas 28 patients; and melanoma, two patients. (**C**) Types of noncutaneous malignancies. Carcinoma, 58 patients; myeloma/leukemia, three patients; and PTLD, eleven patients.\
**Abbreviations:** HTX, heart transplantation; PTLD, posttransplant lymphoproliferative disorder.](dddt-9-093Fig1){#f1-dddt-9-093}

![Kaplan--Meier estimator (5-year follow-up).\
**Notes:** Absence of cutaneous malignancy recurrence in patients with/without mTOR inhibitor therapy after diagnosis of initial tumor.\
**Abbreviation:** mTOR, mammalian target of rapamycin.](dddt-9-093Fig2){#f2-dddt-9-093}

![Kaplan--Meier estimator (total follow-up).\
**Notes:** Survival of patients with noncutaneous malignancy with/without mTOR inhibitor therapy after diagnosis of initial tumor.\
**Abbreviation:** mTOR, mammalian target of rapamycin.](dddt-9-093Fig3){#f3-dddt-9-093}

###### 

Patient characteristics

  Parameter                                                                  All patients (n=381)                                           Patients with malignancy (n=130)   Patients without malignancy (n=251)   *P*-value
  -------------------------------------------------------------------------- -------------------------------------------------------------- ---------------------------------- ------------------------------------- -----------------------------------------------------
  **Recipient data**                                                                                                                                                                                                 
  Recipient age in years, mean ± SD                                          51.2±10.5                                                      54.3±8.3                           49.6±11.2                             \<0.0001[\*](#tfn3-dddt-9-093){ref-type="table-fn"}
  Recipient age ≥50 years, n (%)                                             251 of 381 (65.9%)                                             100 of 130 (76.9%)                 151 of 251 (60.2%)                    0.0011[\*](#tfn3-dddt-9-093){ref-type="table-fn"}
  Recipient sex (male), n (%)                                                300 of 381 (78.7%)                                             115 of 130 (88.5%)                 185 of 251 (73.7%)                    0.0008[\*](#tfn3-dddt-9-093){ref-type="table-fn"}
  BMI, mean ± SD                                                             24.9±3.7                                                       24.9±3.1                           24.9±4.0                              0.9911
  Recipient CMV-positive serostatus, n (%)                                   178 of 381 (46.7%)                                             59 of 130 (45.4%)                  119 of 251 (47.4%)                    0.7071
  Recipient EBV-positive serostatus, n (%)                                   271 of 381 (71.1%)                                             86 of 130 (66.2%)                  185 of 251 (73.7%)                    0.1230
  TREs in the first year, mean ± SD                                          1.0±1.6                                                        1.2±1.7                            0.9±1.5                               0.1512
  \>1 TRE in the first year, n (%)                                           92 of 355 (25.9%)                                              41 of 119 (34.5%)                  51 of 236 (21.6%)                     0.0091[\*](#tfn3-dddt-9-093){ref-type="table-fn"}
  **Donor data**                                                                                                                                                                                                     
  Donor age in years, mean ± SD                                              38.9±13.5                                                      35.5±13.4                          40.6±13.3                             0.0010[\*](#tfn3-dddt-9-093){ref-type="table-fn"}
  Donor age ≥50 years, n (%)                                                 84 of 352[a](#tfn1-dddt-9-093){ref-type="table-fn"} (23.9%)    20 of 117 (17.1%)                  64 of 235 (27.2%)                     0.0355[\*](#tfn3-dddt-9-093){ref-type="table-fn"}
  Donor sex (male), n (%)                                                    165 of 352[a](#tfn1-dddt-9-093){ref-type="table-fn"} (46.9%)   66 of 117 (56.4%)                  99 of 235 (42.1%)                     0.0114[\*](#tfn3-dddt-9-093){ref-type="table-fn"}
  **Recipient comorbidities**                                                                                                                                                                                        
  Coronary artery disease[b](#tfn2-dddt-9-093){ref-type="table-fn"}, n (%)   146 of 381 (38.3%)                                             51 of 130 (39.2%)                  95 of 251 (37.8%)                     0.7925
  Arterial hypertension, n (%)                                               220 of 381 (57.7%)                                             84 of 130 (64.6%)                  136 of 251 (54.2%)                    0.0507
  Dyslipidemia, n (%)                                                        256 of 381 (67.2%)                                             97 of 130 (74.6%)                  159 of 251 (63.3%)                    0.0263[\*](#tfn3-dddt-9-093){ref-type="table-fn"}
  Diabetes mellitus, n (%)                                                   127 of 381 (33.3%)                                             59 of 130 (45.4%)                  68 of 251 (27.1%)                     0.0003[\*](#tfn3-dddt-9-093){ref-type="table-fn"}
  Renal insufficiency, n (%)                                                 222 of 381 (58.3%)                                             86 of 130 (66.2%)                  136 of 251 (54.2%)                    0.0247[\*](#tfn3-dddt-9-093){ref-type="table-fn"}

**Notes:**

Reduced number of patients due to availability of donor data.

Prior to HTX.

Statistically significant (*P*\<0.05).

**Abbreviations:** BMI, body mass index; HTX, heart transplantation; CMV, cytomegalovirus; EBV, Epstein--Barr virus; TREs, treated rejection episodes; n, number; SD, standard deviation.

###### 

Immunosuppressive drug therapy after HTX

  Administration of drug for \>1 year   All patients (n=381)   Patients with malignancy (n=130)   Patients without malignancy (n=251)   *P*-value
  ------------------------------------- ---------------------- ---------------------------------- ------------------------------------- -----------------------------------------------------
  Cyclosporine A                        239/62.7%              92/70.8%                           147/58.6%                             0.0195[\*](#tfn5-dddt-9-093){ref-type="table-fn"}
  Tacrolimus                            149/39.1%              34/26.2%                           115/45.8%                             0.0002[\*](#tfn5-dddt-9-093){ref-type="table-fn"}
  Azathioprine                          152/39.9%              67/51.5%                           85/33.9%                              0.0008[\*](#tfn5-dddt-9-093){ref-type="table-fn"}
  Mycophenolate mofetil                 227/59.6%              59/45.4%                           168/66.9%                             \<0.0001[\*](#tfn5-dddt-9-093){ref-type="table-fn"}
  Steroids                              207/54.3%              85/65.4%                           122/48.6%                             0.0018[\*](#tfn5-dddt-9-093){ref-type="table-fn"}
  mTOR inhibitors                       104/27.3%              19/14.6%                           85/33.9%                              \<0.0001[\*](#tfn5-dddt-9-093){ref-type="table-fn"}

**Note:**

Statistically significant (*P*\<0.05).

**Abbreviations:** HTX, heart transplantation; mTOR, mammalian target of rapamycin; n, number.

###### 

Influence of mTOR inhibitor therapy

  Follow-up           Cutaneous malignancy recurrence         Cutaneous malignancy recurrence with mTOR inhibitor therapy         Cutaneous malignancy recurrence without mTOR inhibitor therapy         *P*-value
  ------------------- --------------------------------------- ------------------------------------------------------------------- ---------------------------------------------------------------------- -----------------------------------------------------
  1-year follow-up    n=7 of 68 (10.3%)                       n=1 of 25 (4.0%)                                                    n=6 of 43 (14.0%)                                                      0.1928
  2-year follow-up    n=15 of 63 (23.8%)                      n=2 of 22 (9.1%)                                                    n=13 of 41 (31.7%)                                                     0.0445[\*](#tfn7-dddt-9-093){ref-type="table-fn"}
  5-year follow-up    n=28 of 50 (56.0%)                      n=6 of 19 (31.6%)                                                   n=22 of 31 (71.0%)                                                     0.0065[\*](#tfn7-dddt-9-093){ref-type="table-fn"}
  10-year follow-up   n=36 of 41 (87.8%)                      n=12 of 14 (85.7%)                                                  n=24 of 27 (88.9%)                                                     0.7683
  Overall follow-up   n=39 of 74 (52.7%)                      n=13 of 27 (48.1%)                                                  n=26 of 47 (55.3%)                                                     0.5520
  **Follow-up**       **Noncutaneous malignancy mortality**   **Noncutaneous malignancy mortality with mTOR inhibitor therapy**   **Noncutaneous malignancy mortality without mTOR inhibitor therapy**   
  1-year follow-up    n=20 of 70 (28.6%)                      n=3 of 27 (11.1%)                                                   n=17 of 43 (39.5%)                                                     0.0104[\*](#tfn7-dddt-9-093){ref-type="table-fn"}
  2-year follow-up    n=28 of 64 (43.8%)                      n=5 of 26 (19.2%)                                                   n=23 of 38 (60.5%)                                                     0.0011[\*](#tfn7-dddt-9-093){ref-type="table-fn"}
  5-year follow-up    n=31 of 55 (56.4%)                      n=6 of 21 (28.6%)                                                   n=25 of 34 (73.5%)                                                     0.0011[\*](#tfn7-dddt-9-093){ref-type="table-fn"}
  10-year follow-up   n=36 of 43 (83.7%)                      n=6 of 10 (60.0%)                                                   n=30 of 33 (90.9%)                                                     0.0204[\*](#tfn7-dddt-9-093){ref-type="table-fn"}
  Overall follow-up   n=37 of 72 (51.4%)                      n=6 of 29 (20.7%)                                                   n=31 of 43 (72.1%)                                                     \<0.0001[\*](#tfn7-dddt-9-093){ref-type="table-fn"}

**Note:**

Statistically significant (*P*\<0.05).

**Abbreviation:** mTOR, mammalian target of rapamycin.

###### 

Multivariate analysis of risk factors

  Variable                      Odds ratio   95% confidence interval   *P*-value
  ----------------------------- ------------ ------------------------- ---------------------------------------------------
  Recipient age (\>50 years)    2.158        1.240--3.754              0.0065[\*](#tfn9-dddt-9-093){ref-type="table-fn"}
  Recipient sex (male)          2.967        1.493--5.897              0.0019[\*](#tfn9-dddt-9-093){ref-type="table-fn"}
  \>1 TRE (in the first year)   2.199        1.302--3.716              0.0032[\*](#tfn9-dddt-9-093){ref-type="table-fn"}
  Diabetes mellitus             1.983        1.222--3.219              0.0056[\*](#tfn9-dddt-9-093){ref-type="table-fn"}

**Note:**

Statistically significant (*P*\<0.05).

**Abbreviation:** TRE, treated rejection episode.
